Tafenoquine plus standard care for babesiosis
Treatments studied
Part of Infections clinical trials.
This study tests whether adding the oral drug tafenoquine to standard care works better than standard care plus a placebo for treating babesiosis, a tick-borne illness. You must be hospitalized with active symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a confirmed Babesia infection.
- You are currently hospitalized for babesiosis treatment and will stay in the hospital for at least the first few days of the study.
- You are willing to take oral medications and complete all study visits and assessments.
- You have not taken azithromycin or atovaquone in the past year to treat babesiosis.
- You are not pregnant and will use effective birth control if you could become pregnant.
- You have no other serious illnesses or allergies that would make it unsafe to take the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication, tafenoquine, to see if it helps people with chronic babesiosis who have ongoing fatigue and other symptoms. It aims to find a better treatment for this tick-borne infection that keeps coming back.
This trial tests ARAKODA (tafenoquine) for people with babesiosis that keeps coming back or doesn't get better with standard treatments. It aims to see if adding this medication helps clear the infection.
This trial tests a combination of antimalarial drugs (tafenoquine plus artemisinin-based combination therapies) to see if it's safe and effective for treating vivax malaria. Participating may help clear the infection and prevent it from coming back.
This study tests how a new malaria drug called tafenoquine moves through the body in healthy adults. It helps provide important safety and dosing information for future use.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This study tests a new combination of two medicines, SJ733 and tafenoquine, to see if it can safely and quickly cure vivax malaria. Vivax malaria can come back, so this treatment aims to prevent that relapse.
Hear when a new Babesiosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.